70NANB22H198

Purpose: Create the University of Delaware (UD) Process Development Testbed with relevant equipment to facilitate process improvements, workforce development, and the testing and demonstration of biopharmaceutical innovations. This facility will leverage the knowledge and experience of the NIIMBL, a public-private partnership focused on the acceleration of biopharmaceutical innovation.

Activities to be performed: This project will procure and install equipment for the UD Process Development Testbed that will serve as a scale-down model of the NIIMBL Process Intensification Testbed. Phase 1 will include finalizing details, specifications, and receiving necessary quotations for equipment. In Phase 2, they will procure and install equipment and perform site acceptance testing.

Expected outcomes: The UD Process Development Testbed will allow smaller scale, more rapid, and more affordable biopharmaceutical experiments to be performed. The testbed will enable workforce development and training, data to be collected and used in process models being developed in the NIIMBL Big Data Program, and new materials (harvest cell culture fluid, chromatography eluates, etc.) produced that can be shared with the biopharmaceutical manufacturing innovation community.

Intended beneficiaries:
1. To NIST: The work plans align with NIST's manufacturing mission space for both advanced manufacturing technology and supply chain security. NIST staff can leverage this project to further the impact of our technical expertise in biomanufacturing, specifically the ongoing development of the research-grade reference cell-line expressing the NIST-MAB to foster innovation in biopharmaceutical manufacturing. The project also leverages NIST's investment in NIIMBL.
2. To awardee: The University of Delaware, as the lead of the NIIMBL consortium, will be able to establish a more cost-efficient capability to do small scale biopharma process-development work on industrially relevant equipment to prepare for runs of the NIIMBL Process Intensification Testbed.
3. To the nation: The pandemic has fully revealed the importance of an agile domestic capacity for the production of biomanufactured therapies such as vaccines. The University of Delaware's leadership of the NIIMBL partnership supports the collaborative development of the next generation processes for manufacturing these critical products. This funding will enable NIIMBL to provide an open collaboration resource for the US bioeconomy that will aid in developing new technologies to support faster to market, higher quality, and extended supply and availability of drug products.

Subrecipient activities: No subrecipient activities will be involved with this grant.

University Of Delaware

NOT APPLICABLE

11.617 - Congressionally-Identified Projects

National Institute of Standards and Technology (NIST) [DOC]

Newark, Delaware 19716-0099 United States

Single Zip Code

2022-NIST-RFA-CIPP-01

Amendment Since initial award the End Date has been extended from 09/30/23 to 09/30/26.